Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.82 |
| ▸ | BLM | P54132 | 2/20 | 0.82 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.82 |
| ▸ | MEN1 | O00255 | 2/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.82 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.82 |
| ▸ | GSR | P00390 | 1/20 | 0.82 |
| ▸ | TSHR | P16473 | 1/20 | 0.82 |
| ▸ | HTT | P42858 | 1/20 | 0.82 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.51 |
| ▸ | PDE4A | P27815 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 3/20 | 0.31 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carmustine SCHEMBL4503 | 0.90 | ALDH1A1 (1.00) | ALDH1A1BLMPMP22MEN1KMT2A | |
| Carmustine SCHEMBL2047318 | 0.90 | ALDH1A1 (1.00) | ALDH1A1BLMPMP22MEN1KMT2A | |
| SCHEMBL6751990 | 0.86 | ALDH1A1 (0.60) | ALDH1A1BLMPMP22MEN1KMT2A | |
| Carmustine SCHEMBL5783727 | 0.85 | ALDH1A1 (0.89) | ALDH1A1BLMPMP22MEN1KMT2A | |
| SCHEMBL9856483 | 0.85 | ALDH1A1 (0.77) | ALDH1A1BLMPMP22MEN1KMT2A | |
| SCHEMBL10005923 | 0.85 | ALDH1A1 (0.77) | ALDH1A1BLMPMP22MEN1KMT2A | |
| SCHEMBL20906025 | 0.85 | ALDH1A1 (0.82) | ALDH1A1BLMPMP22MEN1KMT2A | |
| Ditiomustine SCHEMBL607073 | 0.84 | ALDH1A1 (0.74) | ALDH1A1BLMPMP22MEN1KMT2A | |
| SCHEMBL10878197 | 0.83 | BLM (0.62) | ALDH1A1BLMPMP22MEN1KMT2A | |
| SCHEMBL11148427 | 0.82 | ALDH1A1 (0.72) | ALDH1A1BLMPMP22MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1533 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119706921-A | Preparation method of doped modified tin dioxide nano material for gas sensor, product and application thereof | 上海纳米技术及应用国家工程研究中心有限公司 | 2025-03-28 | — | — | CN | claimed |
| US-20230035723-A1 | Treatment of Pancreatic Cancer | SYNCORE BIOTECHNOLOGY CO., LTD. (TW) | 2023-02-02 | — | — | US | claimed |
| US-20220251187-A1 | P2X7 RECEPTOR TARGETED THERAPY | BIOSCEPTRE (UK) LIMITED (GB) | 2022-08-11 | — | — | US | claimed |
| CN-111202849-B | Albumin-bound nitrosourea antitumor pharmaceutical preparation and preparation method thereof | 四川大学 | 2022-06-03 | — | — | CN | claimed |
| EP-4003531-A1 | P2X7 RECEPTOR TARGETED THERAPY | Biosceptre (Aust) Pty Ltd (AU) | 2022-06-01 | — | — | EP | claimed |
| CN-114173811-A | P2X7 receptor targeted therapy | 生物权威(澳大利亚)有限责任公司 | 2022-03-11 | — | — | CN | claimed |
| CN-111202849-A | Albumin-bound nitrosourea antitumor pharmaceutical preparation and preparation method thereof | 四川大学 | 2020-05-29 | — | — | CN | claimed |
| CN-110267650-A | Cancer of pancreas treatment | 杏国新药股份有限公司 | 2019-09-20 | — | — | CN | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| EP-2827869-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | Brown, Dennis (US) | 2015-01-28 | — | — | EP | claimed |
| US-20040072889-A1 | Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia | PHARMACIA CORPORATION | 2004-04-15 | — | — | US | claimed |
| US-20010049349-A1 | Antioxidant enhancement of therapy for hyperproliferative conditions | CRABTREE ACQUISITION CO, LLC | 2001-12-06 | — | — | US | claimed |
| CN-1261803-A | Antioxidant enhancement of therapy for hyperproliferative conditions | ATHEROGENICS INC (US) | 2000-08-02 | — | — | CN | claimed |
| EP-1019034-A2 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | Atherogenics, Inc. (US) | 2000-07-19 | — | — | EP | claimed |
| WO-1999001118-A9 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | ATHEROGENICS INC (US) | 1999-05-20 | — | — | WO | claimed |
| WO-1999001118-A2 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | ATHEROGENICS, INC. (US) | 1999-01-14 | — | — | WO | claimed |
| US-5691307-A | ANTITUMOR AGENTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-11-25 | — | — | US | claimed |
| EP-0393575-B1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | SEARLE & CO (US) | 1994-03-16 | — | — | EP | claimed |
| EP-0393575-A1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | G.D. Searle & Co. (US) | 1990-10-24 | — | — | EP | claimed |
| US-4150146-A | ANTITUMOR, ANTICARCINOGENIC AGENTS | EISENBRAND GERHARD | 1979-04-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072889-A1 | Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia | PTGS2, PTGES2, PTGER2 | ALDH1A1 496/4885BLM 1609/4885PMP22 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.